Abbott Laboratories Company Insiders
ABT Stock | USD 107.59 0.52 0.49% |
Slightly above 82 percent of Abbott Laboratories' insiders are selling. The analysis of insiders' sentiment of trading Abbott Laboratories stock suggests that a fairly large number of insiders are terrified at this time. Abbott Laboratories employs about 114 K people. The company is managed by 64 executives with a total tenure of roughly 504 years, averaging almost 7.0 years of service per executive, having 1781.25 employees per reported executive.
Robert Ford CEO President, Chief Executive Officer, Chief Operating Officer, Director |
Miles White Chairman Chairman, CEO and Chairman of Executive Committee |
Abbott Laboratories' Insider Buying Vs Selling
18
Selling | Buying |
Latest Trades
2024-03-01 | Daniel Gesua Sive Salvadori | Disposed 963 @ 118.5 | View | ||
2024-02-23 | Andrea F Wainer | Disposed 12500 @ 120 | View | ||
2024-01-29 | Andrea F Wainer | Disposed 42500 @ 112.5 | View | ||
2024-01-23 | Kathy E. Manning | Disposed @ 114 | |||
2024-01-17 | Thomas R. Carper | Disposed @ 113.96 | |||
2023-12-14 | Andrea F Wainer | Disposed 15000 @ 108 | View | ||
2023-12-04 | John R. Curtis | Disposed @ 105.19 | |||
2023-10-26 | Daniel J Starks | Disposed 50000 @ 94.05 | View | ||
2023-10-24 | Greg Stanton | Disposed @ 94.81 | |||
2023-10-03 | Markwayne Mullin | Acquired @ 95.79 | |||
2023-09-26 | Greg Stanton | Acquired @ 96.22 | |||
2023-09-21 | Pete Ricketts | Disposed @ 98.93 | |||
2023-09-13 | John R. Curtis | Acquired @ 102.71 | |||
2023-08-08 | Andrea F Wainer | Disposed 10400 @ 105.03 | View | ||
2023-07-27 | Daniel J Starks | Disposed 50000 @ 113.76 | View | ||
2023-05-02 | Daniel J Starks | Disposed 50000 @ 111.02 | View |
Monitoring Abbott Laboratories' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Abbott Laboratories' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Abbott Laboratories. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Abbott Laboratories' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Abbott |
Abbott Laboratories' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Abbott Laboratories' future performance. Based on our forecasts, it is anticipated that Abbott will maintain a workforce of slightly above 114000 employees by May 2024.Abbott Laboratories' latest congressional trading
Congressional trading in companies like Abbott Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Abbott Laboratories by those in governmental positions are based on the same information available to the general public.
2023-12-04 | Representative John Curtis | Disposed Under $15K | Verify | ||
2023-09-26 | Representative Greg Stanton | Acquired Under $15K | Verify | ||
2023-09-21 | Senator John P Ricketts | Acquired $100K to $250K | Verify | ||
2022-10-17 | Senator Thomas R. Carper | Acquired Under $15K | Verify | ||
2021-10-28 | Representative Kim Schrier | Disposed Under $15K | Verify | ||
2021-03-04 | Representative Carol Devine Miller | Acquired Under $15K | Verify | ||
2021-02-16 | Representative Peter Meijer | Disposed $15K to $50K | Verify | ||
2021-01-05 | Representative Dean Phillips | Acquired Under $15K | Verify | ||
2020-11-05 | Representative Katherine M. Clark | Disposed Under $15K | Verify | ||
2020-09-28 | Representative K. Michael Conaway | Acquired $15K to $50K | Verify | ||
2020-04-07 | Senator Kelly Loeffler | Acquired Under $15K | Verify | ||
2020-03-18 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
2020-03-03 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2019-09-12 | Representative Richard W. Allen | Acquired $15K to $50K | Verify | ||
2019-04-09 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
2018-11-05 | Representative Thomas J. Rooney | Acquired $15K to $50K | Verify | ||
2018-04-05 | Senator Shelley M Capito | Acquired Under $15K | Verify | ||
2017-10-24 | Senator Bill Cassidy | Acquired Under $15K | Verify | ||
2017-10-18 | Senator Tammy Duckworth | Acquired Under $15K | Verify | ||
2017-02-23 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify |
Abbott Laboratories Management Team Effectiveness
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024.Net Income Applicable To Common Shares is likely to gain to about 8.4 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.3 B in 2024.
Abbott Laboratories Workforce Comparison
Abbott Laboratories is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 120,890. Abbott Laboratories totals roughly 114,000 in number of employees claiming about 94% of equities under Health Care industry.
Abbott Laboratories Profit Margins
The company has Net Profit Margin of 0.14 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.14 %, which entails that for every 100 dollars of revenue, it generated $0.14 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.62 | 0.5518 |
|
| |||||
Net Profit Margin | 0.15 | 0.1427 |
|
| |||||
Operating Profit Margin | 0.21 | 0.1615 |
|
| |||||
Pretax Profit Margin | 0.21 | 0.1661 |
|
| |||||
Return On Assets | 0.12 | 0.0782 |
|
| |||||
Return On Equity | 0.26 | 0.1483 |
|
|
Abbott Laboratories Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Abbott Laboratories Price Series Summation is a cross summation of Abbott Laboratories price series and its benchmark/peer.
Abbott Laboratories Notable Stakeholders
An Abbott Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Abbott Laboratories often face trade-offs trying to please all of them. Abbott Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Abbott Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert Ford | President, Chief Executive Officer, Chief Operating Officer, Director | Profile | |
Miles White | Chairman, CEO and Chairman of Executive Committee | Profile | |
Roger Bird | Senior Vice President - U.S. Nutrition | Profile | |
Heather Mason | Senior Vice President - Abbott Diabetes Care | Profile | |
JeanYves Pavee | Senior Vice President - Established Pharmaceuticals, Developed Markets | Profile | |
Stephen Fussell | Executive Vice President - Human Resources | Profile | |
Thomas Frinzi | Senior Vice President - Abbott Medical Optics | Profile | |
Murthy Simhambhatla | Senior Vice President - Abbott Medical Optics | Profile | |
Michael Rousseau | President - Cardiovascular and Neuromodulation | Profile | |
Hubert Allen | Executive Vice President, General Counsel, Secretary | Profile | |
Charles Foltz | Senior Vice President - Abbott Vascular | Profile | |
Brian Yoor | Chief Financial Officer, Executive Vice President - Finance | Profile | |
Jared Watkin | Senior Vice President - Diabetes Care | Profile | |
Scott White | Senior Vice President - International Nutrition | Profile | |
Deepak Nath | Senior Vice President - Abbott Vascular | Profile | |
Jaime Contreras | Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | Profile | |
Andrew Lane | Senior Vice President - Established Pharmaceuticals, Emerging Markets | Profile | |
Georges Vos | Senior Vice President - Established Pharmaceuticals, Emerging Markets | Profile | |
Eric Fain | Senior Vice President Group President - Cardiovascular and Neuromodulation | Profile | |
John Capek | Executive Vice President - Ventures | Profile | |
Joseph Manning | Senior Vice President - Abbott Nutrition International | Profile | |
Michael Warmuth | Executive Vice President - Established Pharmaceuticals | Profile | |
Robert Funck | Chief Financial Officer, Executive Vice President - Finance | Profile | |
Daniel Salvadori | Senior Vice President - Established Pharmaceuticals, Latin America. | Profile | |
Richard Ashley | Executive VP of Corporate Devel. | Profile | |
Brian Blaser | Executive VP of Diagnostic Products | Profile | |
Thomas Freyman | Executive VP of Fin. and Admin. | Profile | |
Samuel Scott | Independent Director | Profile | |
James Farrell | Independent Director | Profile | |
Phebe Novakovic | Independent Director | Profile | |
Roxanne Austin | Independent Director | Profile | |
Sally Blount | Independent Director | Profile | |
Daniel Starks | Independent Director | Profile | |
Robert Alpern | Independent Director | Profile | |
Glenn Tilton | Independent Director | Profile | |
Darren McDew | Independent Director | Profile | |
Patricia Gonzalez | Independent Director | Profile | |
Nancy McKinstry | Independent Director | Profile | |
Michelle Kumbier | Independent Director | Profile | |
Edward Liddy | Independent Director | Profile | |
John Stratton | Independent Director | Profile | |
William Osborn | Lead Independent Director | Profile | |
Erica Battaglia | VP Officer | Profile | |
Christopher Scoggins | Senior Vice President - Rapid Diagnostics | Profile | |
Michael Dale | Senior Vice President - Structural Heart | Profile | |
Sammy Karam | Senior Vice President - Established Pharmaceuticals, Emerging Markets | Profile | |
Michael Pederson | Senior Vice President - Electrophysiology and Heart Failure | Profile | |
Lisa Earnhardt | Executive Vice President - Medical Devices | Profile | |
Alejandro Wellisch | Senior Vice President - Established Pharmaceuticals, Latin America | Profile | |
Christopher Calamari | Senior Vice President - U.S. Nutrition | Profile | |
Charles Brynelsen | Senior Vice President - Abbott Vascular | Profile | |
Gregory Ahlberg | Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | Profile | |
Philip Boudreau | Vice President - Finance, Controller | Profile | |
John Ginascol | Executive Vice President - Core Diagnostics | Profile | |
Michael Roman | Independent Director | Profile | |
Mary Moreland | Executive Vice President of Human Resources | Profile | |
Sabina Ewing | Senior Officer | Profile | |
Randel Woodgrift | Senior Vice President - CRM | Profile | |
Elaine Leavenworth | VP Officer | Profile | |
Scott Leinenweber | Acquisitions Licensing | Profile | |
James Young | VP Officer | Profile | |
Louis Morrone | Senior Vice President - Rapid Diagnostics | Profile | |
Andrea Wainer | Executive Vice President - Rapid and Molecular Diagnostics | Profile | |
Melissa Brotz | Vice Marketing | Profile |
About Abbott Laboratories Management Performance
The success or failure of an entity such as Abbott Laboratories often depends on how effective the management is. Abbott Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Abbott management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Abbott management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.14 | 0.17 | |
Return On Capital Employed | 0.11 | 0.10 | |
Return On Assets | 0.08 | 0.12 | |
Return On Equity | 0.15 | 0.26 |
The data published in Abbott Laboratories' official financial statements usually reflect Abbott Laboratories' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Abbott Laboratories. For example, before you start analyzing numbers published by Abbott accountants, it's critical to develop an understanding of what Abbott Laboratories' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Abbott Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Abbott Laboratories' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Abbott Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Abbott Laboratories. Please utilize our Beneish M Score to check the likelihood of Abbott Laboratories' management manipulating its earnings.
Abbott Laboratories Workforce Analysis
Traditionally, organizations such as Abbott Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Abbott Laboratories within its industry.Abbott Laboratories Manpower Efficiency
Return on Abbott Laboratories Manpower
Revenue Per Employee | 351.8K | |
Revenue Per Executive | 626.7M | |
Net Income Per Employee | 50K | |
Net Income Per Executive | 89.1M | |
Working Capital Per Employee | 77.4K | |
Working Capital Per Executive | 138M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Abbott Stock analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Abbott Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abbott Laboratories. If investors know Abbott will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abbott Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Dividend Share 2.12 | Earnings Share 3.21 | Revenue Per Share 23.183 | Quarterly Revenue Growth 0.022 |
The market value of Abbott Laboratories is measured differently than its book value, which is the value of Abbott that is recorded on the company's balance sheet. Investors also form their own opinion of Abbott Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Abbott Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abbott Laboratories' market value can be influenced by many factors that don't directly affect Abbott Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abbott Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.